Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases.
Brain metastases
Hypofractionated stereotactic radiotherapy
Simultaneously integrated boost
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
22 May 2023
22 May 2023
Historique:
received:
07
01
2023
accepted:
17
04
2023
medline:
24
5
2023
pubmed:
23
5
2023
entrez:
22
5
2023
Statut:
epublish
Résumé
In stereotactic radiotherapy, dose is prescribed to an isodose surrounding the planning target volume (PTV). However, the desired dose inhomogeneity inside the PTV leaves the specific dose distribution to the gross tumor volume (GTV) unspecified. A simultaneously integrated boost (SIB) to the GTV could solve this shortcoming. In a retrospective planning study with 20 unresected brain metastases, a SIB approach was tested against the classical prescription. For all metastases, the GTV was isotropically enlarged by 3 mm to a PTV. Two plans were generated, one according to the classical 80% concept with 5 times 7 Gy prescribed (on D The SIB concept was superior to the classical 80% concept concerning dose homogeneity inside GTV: Heterogeneity index of GTV was in the SIB concept (median 0.0513, range 0.0397-0.0757) significantly (p = 0.001) lower than in the 80% concept (median 0.0894, range 0.0447-0.1872). Dose gradients around PTV were not inferior. The other examined measures were comparable. Our stereotactic SIB concept better defines the dose distribution inside PTV and can be considered for clinical use.
Sections du résumé
BACKGROUND
BACKGROUND
In stereotactic radiotherapy, dose is prescribed to an isodose surrounding the planning target volume (PTV). However, the desired dose inhomogeneity inside the PTV leaves the specific dose distribution to the gross tumor volume (GTV) unspecified. A simultaneously integrated boost (SIB) to the GTV could solve this shortcoming. In a retrospective planning study with 20 unresected brain metastases, a SIB approach was tested against the classical prescription.
METHODS
METHODS
For all metastases, the GTV was isotropically enlarged by 3 mm to a PTV. Two plans were generated, one according to the classical 80% concept with 5 times 7 Gy prescribed (on D
RESULTS
RESULTS
The SIB concept was superior to the classical 80% concept concerning dose homogeneity inside GTV: Heterogeneity index of GTV was in the SIB concept (median 0.0513, range 0.0397-0.0757) significantly (p = 0.001) lower than in the 80% concept (median 0.0894, range 0.0447-0.1872). Dose gradients around PTV were not inferior. The other examined measures were comparable.
CONCLUSION
CONCLUSIONS
Our stereotactic SIB concept better defines the dose distribution inside PTV and can be considered for clinical use.
Identifiants
pubmed: 37217934
doi: 10.1186/s13014-023-02266-9
pii: 10.1186/s13014-023-02266-9
pmc: PMC10204235
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
88Informations de copyright
© 2023. The Author(s).
Références
Cancer Radiother. 2021 Feb;25(1):1-7
pubmed: 33257109
J Neurosurg. 2006 Dec;105 Suppl:194-201
pubmed: 18503356
J Appl Clin Med Phys. 2020 Jan;21(1):26-35
pubmed: 31859456
Pract Radiat Oncol. 2020 Jan - Feb;10(1):36-43
pubmed: 31586666
J Neurosurg. 2006 Jun;104(6):907-12
pubmed: 16776334
Front Oncol. 2020 Sep 30;10:559193
pubmed: 33102223
Radiat Oncol. 2020 Apr 17;15(1):82
pubmed: 32303236
Strahlenther Onkol. 2018 Oct;194(10):929-943
pubmed: 30116827
Int J Radiat Oncol Biol Phys. 2021 May 1;110(1):68-86
pubmed: 32921513
Radiat Oncol. 2011 May 15;6:48
pubmed: 21575163
Neurosurgery. 2008 May;62(5):1018-31; discussion 1031-2
pubmed: 18580799
Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):291-8
pubmed: 10802351
Z Med Phys. 2020 Feb;30(1):70-86
pubmed: 31843265
Strahlenther Onkol. 2021 Sep;197(9):836-846
pubmed: 34196725
Lancet Oncol. 2014 Apr;15(4):387-95
pubmed: 24621620
Strahlenther Onkol. 2014 Jun;190(6):521-32
pubmed: 24715242
J Neurooncol. 2020 Sep;149(3):447-453
pubmed: 32979130
Strahlenther Onkol. 2007 Nov;183(11):625-30
pubmed: 17960338
Strahlenther Onkol. 2019 Mar;195(3):193-198
pubmed: 30649567
Cureus. 2021 Jun 2;13(6):e15399
pubmed: 34249548